MedTrace Logo

Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

NCT00469456 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2009-12-24

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease

Conditions

Interventions

DRUG

Memantine

Memantine 20mg (10mg twice daily) oral administration for 12 weeks

DRUG

placebo

Placebo oral administration twice daily for 12 weeks

Sponsors & Collaborators

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • F C Potocnik

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Australia
  • New Zealand
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00469456 on ClinicalTrials.gov